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Abstract
Background: Cross-resistance to quinolones and beta-lactams is frequent in Enterobacteriaceae, due to the wide use of
these antibiotics clinically and in the food industry. Prescription of one of these categories of antibiotic may
consequently select for bacteria resistant to both categories. Genetic mechanisms of resistance may be secondary to a
chromosomal mutation located in quinolone resistance determining region of DNA gyrase or topoisomerase IV or to a
plasmid acquisition. The insertion sequence ISCR1 is often associated with qnr and may favour its dissemination in
Gram-negative bacteria. The aim of this study was to determine the genetic mechanism of quinolone resistance among
extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in the Central African Republic.
Findings: Among seventeen ESBL-producing Enterobacteriaceae isolated from urine, pus or stool between January
2003 and October 2005 in the Central African Republic, nine were resistant to ciprofloxacin (seven from community
patients and two from hospitalized patients). The ESBL were previously characterized as CTX-M-15 and SHV-12.
Susceptibility to nalidixic acid, norfloxacin and ciprofloxacin, and the minimal inhibitory concentrations of these
drugs were determined by disc diffusion and agar dilution methods, respectively. The presence of plasmid-borne
ISCR1-qnrA region was determined by PCR and amplicons, if any, were sent for sequencing. Quinolone resistance
determining region of DNA gyrase gyrA gene was amplified by PCR and then sequenced for mutation
characterization. We found that all CTX-M-producing strains were resistant to the tested quinolones. All the isolates
had the same nucleotide mutation at codon 83 of gyrA. Two Escherichia coli strains with the highest MICs were
shown to harbour an ISCR1-qnrA1 sequence. This genetic association might favour dissemination of resistance to
quinolone and perhaps other antibiotics among Enterobacteriaceae.
Conclusions: This study shows that at least two mechanisms might explain the emerging resistance of
Enterobacteriaceae to quinolones in the CAR. Beside the classical topoisomerase mutation, the cause may be
acquisition of a plasmid-borne qnrA1. Clinicians and bacteriologists should be made aware of possible
dissemination of ISCR1-qnrA1 among Enterobacteriacae.
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Background
Quinolones and beta-lactams are widely used antibiotics
for the treatment of bacterial infections and are also
extensively used in the food-processing industry. Their
wide use has triggered increased bacterial resistance
worldwide [1]. Quinolone resistance and extended-spec-
trum beta-lactamase (ESBL) production are often asso-
ciated in Enterobacteriaceae [1]. The prescription of
quinolones may consequently select bacteria that are
not only quinolone-resistant but also beta-lactam-resis-
tant and vice versa. The biological mechanisms of resis-
tance to quinolones include impermeability, active
efflux, target modification and antibiotic neutralization.
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Genetic determination of quinolone resistance is gener-
ally linked to chromosomal mutations affecting the qui-
nolone resistance-determining regions (QRDR) of DNA
gyrase (GyrA and GyrB) and topoisomerase IV (ParC
and ParE) [1]. Mutations in gyrA, the gene encoding for
the A subunit of DNA gyrase are the most common
mechanism involved in quinolone resistance among
Gram negative bacteria [2].
In 1994, the plasmid-borne quinolone resistance genes
qnr were identified [1]. The insertion sequence ISCR1
has often been characterized in the genetic environment
of qnr and may be involved in dissemination of the gene
in Gram-negative bacteria [3].
Quinolone resistance was first identified in the CAR in
2003, among clinical ESBL-producing Enterobacteria-
ceae. The aim of this study was to determine the genetic
mechanism of quinolone resistance of these strains iso-
lated in the Central African Republic (CAR).
Methods
Of the seventeen ESBL-producing Enterobacteriaceae
isolated from urine, pus or stool samples between Janu-
ary 2003 and October 2005 at the Institut Pasteur de
Bangui and previously characterized as CTX-M-15 and
SHV-12, nine were resistant to ciprofloxacin (eight
Escherichia coli and one Klebsiella pneumoniae) [4].
Seven E.coli strains were isolated from community
patients and the two others were isolated from hospita-
lized patients.
Antibiotic susceptibility was determined by the diffu-
sion disc method (Comité de l’Antibiogramme de la
Société Française de Microbiologie). The minimal inhi-
bitory concentrations (MICs) of nalidixic acid, norfloxa-
cin and ciprofloxacin were measured by the agar
dilution method.
PCR was carried out on genomic DNA extracted with
the commercial Qiagen DNA Mini Kit (Qiagen, Courta-
boeuf, France) at 94 °C for 5 min, 35 cycles at 94 °C for
30 s, 55 °C for 40 s and extension at 72 °C for 60 s, fol-
lowed by 72 °C for 7 min.
The ciprofloxacin-resistant isolates were screened for
the qnrA gene by PCR with specific primers targeting
ISCR1, 5’-TGAAACAGAAAACAGCCAAGG-3’ (ISC
R1qnr upper), and qnrA, 5’-GCAGCACTATTACTC-
CAAGG-3’ (ISCR1qnr lower). The primers targeting
ISCR1-qnrA1 were designed with Oligo-4 software. The
sequences encoding QRDR of DNA gyrase were ampli-
fied with gyrA6 5’-CGA CCT TGC GAG AGA AAT-3’
and gyrA631R 5’-GTT CCA TCA GCC CTT CAA-3’
[5].
All amplicons were sequenced at MWG Biotech
France (http://www.mwg-biotech.com) and analysed
with program ChromasPro 2.0 and blastN software
(http://gb-admin@ncbi.nlm.nih.gov) (GenBank accession
numbers for the sequenced ISCR1-qnrA1 region are
JF728153 and JF728154).
All patients have given their agreement to participate
in this study prior the samples collection. This study
was reviewed and approved by the scientific committee
board of University of Bangui in charge of the validation
of scientific protocol studies in the CAR.
Results and discussion
Susceptibility testing showed that all CTX-M-producing
strains were resistant to nalidixic acid, norfloxacin and
ciprofloxacin. The MIC of nalidixic acid and norfloxacin
was 64 μg/ml and that of ciprofloxacin was 32 μg/ml for
six E. coli and the K. pneumoniae strains. For two E. coli
isolates, the MICs were higher, and PCR targeting
ISCR1-qnrA amplified a 1050-bp fragment from these
two isolates which was shown by DNA sequence analy-
sis to be ISCR1-qnrA1. We could not determine the
MICs values of the two qnrA-positive E. coli by the agar
dilution method because they exceeded the highest con-
centrations of antibiotics tested in this study (32 μg/ml
for ciprofloxacin and 64 μg/ml for the nalidixic acid).
Other publications have shown that qnrA increased the
MICs of quinolones by 10-fold in Enterobacteriaceae
[6]. The combination of an insertion sequence ISCR1
with qnrA1 could ensure dissemination of quinolone
resistance to both ESBL-producing and ESBL-negative
Enterobacteriaceae. The ISCR1 element is also capable
of mobilizing qnrA1 in multiple drug resistance regions,
generally located on plasmids that mediate resistance to
multiple antibiotics.
Sequence analysis of the gene portion encoding the
QRDR of GyrA showed the same amino acid change in
GyrA (Ser83-Leu) in all our isolates. Nucleotide muta-
tions at codon 83 are the commonest GyrA substitu-
tions found in quinolone-resistant E. coli and the serine
residue is most commonly substituted by a leucine [7].
Conclusion
We have shown that the emerging resistance of Entero-
bacteriaceae to quinolones in the CAR may be due to a
topoisomerase mutation or a plasmid-borne qnrA1
acquisition. It would be interesting to sequence the
DNA gyrase gyrB and topoisomerase IV parC and parE
genes, to screen for the other qnr genes (B and S) and
to characterize the environment of ISCR1-qnrA1, which
has already been found in several sul1-type complex
integrons. The possible dissemination of ISCR1-qnrA1
among Enterobacteriacae requires vigilance by bacteriol-
ogy laboratories in the CAR. It will also be important to
inform clinicians of the potential risk associated with
prescribing quinolones and beta-lactams.
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